(Q39696728)

14 September 2017

title

Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor (English)

1 reference

14 September 2017

Makiko Kobayashi

1

1 reference

14 September 2017

Ikuko Takahashi-Suzuki

2

1 reference

14 September 2017

Toshiyasu Shimomura

3

1 reference

14 September 2017

Yoshikazu Iwasawa

4

1 reference

14 September 2017

Hiroshi Hirai

5

1 reference

14 September 2017

publication date

4 June 2010

1 reference

Investigational New Drugs

14 September 2017

published in

1 reference

14 September 2017

volume

29

1 reference

14 September 2017

issue

5

1 reference

14 September 2017

page(s)

921-931

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

14 September 2017

1 reference

Distinct roles for cyclin-dependent kinases in cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

The regulation of E2F by pRB-family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Targeting the cell cycle for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Selected novel anticancer treatments targeting cell signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

CDK9 (PITALRE): a multifunctional cdc2-related kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Cyclin-dependent kinase 5 promotes insulin exocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

CDK inhibitors in cancer therapy: what is next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Survival signaling in resting B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Control of lymphocyte development by nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9448-9

Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure

21 January 2018

1 reference

12 December 2020

Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.

1 reference

12 December 2020

Rapid nuclear translocation and increased activity of cyclin-dependent kinase 6 after T cell activation

1 reference

12 December 2020

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo

1 reference

12 December 2020

Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells

1 reference

12 December 2020

Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation

1 reference

12 December 2020

Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts

1 reference

12 December 2020

Development of cell-cycle inhibitors for cancer therapy

1 reference

12 December 2020

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.

1 reference

12 December 2020

Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells

1 reference

12 December 2020

Transcriptional signature of flavopiridol-induced tumor cell death.

1 reference

12 December 2020

The Pezcoller lecture: cancer cell cycles revisited

1 reference

12 December 2020

Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad

1 reference

12 December 2020

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

1 reference

12 December 2020

Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9

1 reference

12 December 2020

10.1007/S10637-010-9448-9

Identifiers

DOI

1 reference

14 September 2017

1 reference